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Abstract
Purpose Moderate hyperprolactinaemia (2–5 times upper limit of normal) occurring in a patient with a normal pituitary 
MRI is generally considered to be due to a lesion below the level of detection of the MRI scanner assuming macroprolactin 
and stress have been excluded. Most patients with mild-to-moderate hyperprolactinaemia and a normal MRI respond to 
dopamine agonist therapy. We present the rare case of a patient who had prolactin elevation typical of a prolactin-secreting 
pituitary macroadenoma,with a normal cranial MRI, and in whom the prolactin rose further with dopamine agonist treat-
ment. Subsequent investigations revealed ectopic hyperprolactinaemia to a uterine tumor resembling ovarian sex cord tumor 
(UTROSCT) which resolved following tumor resection. Although mostly considered to be benign, the UTROSCT recurred 
with recurrent hyperprolactinaemia and intraabdominal metastases.
Methods We have systematically and critically reviewed existing literature relating to ectopic hyperprolactinaemia in general 
and UTROCST specifically.
Results Fewer than 80 cases of UTROSCTs have been reported globally of which about 23% have shown malignant behav-
iour. There are fewer than 10 cases of paraneoplastic hyperprolactinaemia originating from uterine neoplasms including one 
other case of ectopic hyperprolactinaemia to a UTROSCT.
Conclusions Our case demonstrates the importance of screening for extracranial hyperprolactinaemia in the context of: 
(1) substantially raised prolactin (10× ULN) and (2) normal cranial MRI assuming macroprolactin has been excluded. The 
majority of extracranial ectopic prolactin-secreting tumors occur in the reproductive organs.
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Introduction
The human prolactin (PRL) gene, located on chromosome 
6 [1], apparently rose from a single common ancestral gene 
giving rise to the relatively homologous PRL, growth hor-
mone (GH), and the placental lactogen-related proteins [2]. Georgios K. Dimitriadis and Delane S. Wajman contributed 
equally and are joined first authors.
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Several factors influence PRL, gene expression, including 
oestrogen, dopamine, thyrotropin-releasing hormone (TRH), 
and thyroid hormones [3]. PRL secretion is under the inhibi-
tory control of dopamine, which is produced mainly by the 
tuberoinfundibular cells and the hypothalamic tuberohypo-
physeal dopaminergic system [4, 5]. High concentrations 
of circulating prolactin are typically associated with either 
prolactin secreting pituitary tumors or interference with the 
dopaminergic control of prolactin from normal pituitary 
such as pituitary stalk disconnection and dopamine agonist 
medications, as well as other conditions including primary 
hypothyroidism, uraemia and hepatic insufficiency.
Apparently high levels of prolactin may be due to excess 
circulating prolactin complexes (‘macroprolactin’) which 
need to be differentiated from true hyperprolactinaemia. 
Increased prolactin may also rise due to acute medical stress 
and therefore diagnostic levels of prolactin should be ideally 
taken after intravenous cannulation [6].
The ectopic production of hormones from tissues that 
are not generally considered to be part of their usual cel-
lular behaviour are a consistent theme in endocrinology 
and lead to distinct clinical syndromes. These syndromes 
can originate from either endocrine or non-endocrine neo-
plasms. They can precede, occur concomitantly, or present 
at a later stage of neoplasm development, and along with the 
secreted substances constitute the biological ‘fingerprint’ of 
the neoplasm. Their detection can facilitate early diagnosis 
of the underlying neoplasia, monitor response to treatment, 
and/or detect early recurrences following successful initial 
management [7].
Ectopic prolactin may arise from prolactinoma cells that 
have arisen intracranially or within the sinuses and these 
likely arise from normal pituitary cells that are remnants 
left during the development of the pituitary from Rathke’s 
pouch. These have the cellular appearance of typical prolac-
tinoma but are “extrapituitary”. There are in addition a very 
small number of cases where prolactin has been released 
from tissues that do not usually express prolactin and are 
most frequently associated with neoplasms of the female 
reproductive system. In this report we have identified hyper-
prolactinaemia arising due to ectopic production from a 
malignant uterine tumor resembling ovarian sex cord tumor 
(UTROSCT) [8].
Case presentation
A 46-year-old Caucasian female presented to the endocrine 
outpatient clinic with a 12 month history of secondary amen-
orrhoea. She was a mother of two children following sponta-
neous conception and previously used a progestin releasing 
intrauterine device which had been removed 6 months before 
amenorrhoea was first observed. She was not on any regu-
lar medications. On initial biochemistry tests, prolactin was 
223 mcg/L (reference range 4–23 mcg/L for premenopausal 
non-pregnant women) without macroprolactin complexes 
following a precipitation test. LH & FSH were low (0.1 and 
1.5 mIU/L respectively with reference range 2–12 mIU/L 
during follicular phase) and oestradiol was undetectable 
(< 55 nmol/L, reference range > 100 nmol/L for premeno-
pause), with normal thyroid function tests (TSH: 1.04 mU/L; 
reference range 0.30–5.50 mU/L and fT4: 13.4 pmol/L; ref-
erence range 9–26 pmol/L). She had normal visual fields on 
confrontation and no other clinical or biochemical features 
of pituitary dysfunction. A subsequent contrast-enhanced 
pituitary magnetic resonance imaging (MRI) scan showed 
normal pituitary gland appearances without evidence of a 
focal lesion (Fig. 1a, b).
She was started on cabergoline 250 mcg twice weekly, 
which was subsequently increased to 500 mcg twice 
weekly. Repeat serum prolactin 5 months and 8 months 
later showed a progressive rise to 313 mcg/L and 454 
Fig. 1  Targeted MRI exami-
nation of the pituitary region 
including coronal and sagittal 
T1-weighted sequence post-con-
trast enhanced images revealing 
no abnormalities
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mcg/L respectively, rising further to 546 mcg/L despite 
further intensification of dopamine agonist treatment. 
Compliance with medication was confirmed and a repeat 
pituitary MRI scan was again normal.
At this stage an alternative source of prolactin secre-
tion was considered and since ectopic prolactin has been 
recognised as being a feature of neoplasms of the repro-
ductive organs, further clinical assessment revealed a 
palpable pelvic mass in the lower abdomen rising to the 
umbilicus. Pelvic computerised tomography (CT) scan 
showed an 11 cm uterine mass initially reported as a 
fibroid which raised the suspicion of an ectopic source 
of hyperprolactinaemia (Fig. 2). She underwent total hys-
terectomy and histological examination showed a well-
circumscribed but encapsulated UTROSCT in which cells 
were organized in sheets, cords, nests, and trabeculae. 
Ki-67 was < 5%, and mitotic count was 6 per 10HPF 
(Fig. 3). Immunohistochemistry (IHC) was negative for 
prolactin, melanA, and Calretinin. It was positive for inhi-
bin in the trabecular areas, CD99 was focally positive, 
desmin was positive, CD10 focally weakly positive, ER, 
PR, AE1/AE3 and SMA were focally positive (Table 1). 
Despite negative tissue staining for prolactin, postop-
eratively serum prolactin concentration was entirely 
suppressed at 3 mcg/L (Fig. 4). In view of the finding 
of a neoplasm with malignant potential, further surgery 
was recommended and she underwent bilateral salpingo-
oophorectomy. After 2 years however, the patient was 
found to have evidence of intraabdominal recurrent tumor 
and was then proven again to have elevated prolactin.
Methods
We conducted systematic searches of the Medical Litera-
ture Analysis and Retrieval System Online (MEDLINE) and 
Excerpta Medica (EMBASE). The Medical Subject Head-
ings (MeSH) search terms included ectopic, or paraneoplas-
tic, and hyperprolactinaemia, or hyperprolactinemia and the 
search strategy for MEDLINE was constructed as follows: 
((((ectopic) OR paraneoplastic) AND hyperprolactinaemia) 
OR hyperprolactinemia). Our systematic search revealed a 
total of 132 reports in the literature, most of which of cranial 
origin, including ectopic pituitary adenomas [9–11]. Our 
search identified six other reports of hyperprolactiaemia to 
a uterine neoplasm with only one case reporting this being 
secondary to a UTROSCT. These reports are summarised 
in Table 2.
Discussion
Hyperprolactinaemia is a common presenting problem in 
endocrine practice. It is more common in women where 
the incidence is 0.2% in the general adult population and 
17% in women with a reproductive disorder [12]. Once 
stress-related hyperprolactinaemia and macroprolactin are 
excluded, the most frequent cause is a prolactin secreting 
pituitary adenoma [13, 14].
An alternative aetiology is that of idiopathic hyperprol-
actinaemia, responsible for 3.6% of all cases [13, 14]. It is 
defined as clinical or asymptomatic hyperprolactinaemia in 
the absence of macroprolactin with negative pituitary imag-
ing after pathological causes such as hypothyroidism, renal, 
Fig. 2  Pelvic CT examination 
revealing a well-defined 11 cm 
pelvic mass without further 
abnormalities
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and severe liver insufficiency as well as other hyperprolac-
tinaemia causes have been previously excluded [14]. Small 
microprolactinomas less than 3 mm in max diameter, below 
the threshold of detection on MRI, are the likely cause [14]. 
An alternative cause of the “idiopathic hyperprolactinemia” 
phenomenon may be the presence of anti pituitary antibodies 
[15]. While the normal endometrium retains the ability to 
discharge PRL in the late luteal phase. Studies on PRL levels 
in the peritoneal fluid show no evidence that the implants 
secrete prolactin [16].
“Ectopic” or paraneoplastic secretion of a hormone refers 
to the production by a cell type that does not typically pro-
duce that substance or produces it at low concentrations. 
Ectopic hormone production may also by a hormone-produc-
ing cell whose “machinery” has been co-opted to produce 
another hormone. An example of this is the production of 
adrenocorticotrophic hormone (ACTH) by a broad spectrum 
of tumor types with some degree of neuroendocrine differ-
entiation, such as small cell lung carcinomas (SCLCs) [7].
In this report we describe a patient whose presentation 
was due to hyperprolactinaemia due to a UTROSCT which 
initially resoved after tumor resection but then demonstrated 
malignant behaviour.
Ectopic hyperprolactinaemia is rare and can be consid-
ered intracranial or extracranial. Ectopic intracranial pro-
duction of prolactin arises from tumors that have typical 
features of pituitary prolactinomas and are thought to origi-
nate from the neoplastic proliferation of pituitary rests along 
the embryological path of the pituitary development [17, 
18]. Approximately 60% of reported ectopic pituitary adeno-
mas are seen in the sphenoid sinus and suprasellar region, 
and 30% can be found in the clivus, nasal cavity, cavernous 
Fig. 3  Immunohistochemical staining and molecular analyses. Immu-
nostaining in cord-like and solid elements: endometrial glands are 
infiltrated by WT1-positive tumor cells; magnification ×1.25 (a), 
CD10 shows variable positivity in areas; magnification ×1
(b). Immunostaining in cord-like and solid elements: α-smooth mus-
cle actin is focally positive in the solid lesion; magnification ×10 (c), 
whereas cytokeratin (AE1/AE3) is expressed diffusely in the cord-
like area; magnification ×10 (d)
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sinus, parasellar region, and sphenoid wing [19]. Rare sites 
beyond the migrational tract have also been described, 
including those in the petrosal temporal bone [20], superior 
orbital fissure [21], third ventricle [22], and temporal lobe 
[23]. These tumors typically respond to dopamine agonist 
to the same extent as eutopic prolactinomas.
Extracranial hyperprolactinaemia is even rarer and has 
previously been reported in both benign and malignant neo-
plasms [24, 25]. Elms et al. recently reported a case of sig-
nificant hyperprolactinaemia from a benign cystic teratoma 
containing a prolactin-secreting pituitary adenoma with 
resolution following resection of the tumor [26]. Kallenberg 
et al. and Gururaj et al. also reported hyperprolactinaemia 
to an ovarian teratoma [27, 28]. Hyperprolactinaemia from 
uterine dermoid tumors has been reported by others previ-
ously [26]. Dermoid tumors can differentiate into other types 
of cells acquiring their secretory components, thus making 
them a potential source of ectopic hyperprolactinaemia [29, 
30]. In the limited previous reports of ectopic extracranial 
prolactin secretion in the published literature, ovarian germ 
cell tumors associated with hyperprolactinaemia had micro-
scopic pituitary elements [25–28]. Turkington et al. have 
reported two cases of ectopic prolactin production. In one 
case, from an undifferentiated bronchial carcinoma and 
another case of hyperprolactinaemia from a hypernephroma 
[22].
There have been fewer than 10 cases where excess prol-
actin has been attributed to a uterine neoplasm as summa-
rised in Table 2. Interestingly, in all these cases the tumors 
failed to stain for prolactin despite the hyperprolactinae-
mia resolving after surgery. Cordiano reported the case of 
hyperprolactinaemia to a uterine leiomyoma in a patient 
with a co-existent pituitary microadenoma not responding 
to treatment with bromocriptine [31]. Herzog also reported 
hyperprolactinaemia to a uterine leiomyoma presenting with 
migraine and no response to treatment with bromocriptine 
[32]. Symptoms resolved following a hysterectomy. Sato 
et al., report the case of a Japanese female patient with 
refractory hyperprolactinaemia and negative MRI for pitui-
tary neoplasm with symptom resolution following hyster-
ectomy for a leiomyoma [33]. Sendura et al. report the case 
of a patient with persistent hyperprolactinaemia, secondary 
amenorrhoea, and galactorrhoea despite being treated with 
bromocriptine and cabergoline previously. Hyperprolacti-
naemia was secondary to a giant leiomyoma with negative 
immunohistochemistry for PRL [34]. Simsir et al., report 
the case of hyperprolactinaemia with associated secondary 
amenorrhoea and galactorrhoea to a leiomyosarcoma with 
complete resolution of symptoms following hysterectomy. 
Immunohistochemistry was negative for PRL [35]. O’meara 
et al. report the only other case of hyperprolactinaemia with 
abdominal discomfort, galactorrhea and metrorrhagia to a 
UTROSCT with complete resolution of symptoms following 
total abdominal hysterectomy. Immunohistochemistry was 
negative for PRL [36]. Under certain conditions, specific 
alterations of gene function may inappropriately herald the 
unscheduled appearance of a gene product at an unusual 
Table 1  Source and condition of antibodies, and summary of immu-
nohistochemistry
Antibody Source Working dilution IHC result
CK (AE1/AE3) Progen 1:600 ++
CD10 Roche Prediluted  +  (focally)
Desmin Nichirei Prediluted  ++
αSMA Nichirei Prediluted  +  (focally)
Calretinin Nichirei 1:50 −
CD56 Nichirei Prediluted  + (focally)
WT1 Nichirei Prediluted  + (focally)
CD99 (MIC2) DAKO 1:100  + (focally)
ER Roche Prediluted  + (focally)
PgR Roche Prediluted  + (focally)
PRL Roche Prediluted −
Inhibin DAKO 1:25  ++ 
Melan A Novo 1:20
Fig. 4  Prolactin values in mcg/L 
(reference rage 4–23 mcg/L for 
premenopausal non-pregnant 
women) during different disease 
stages, illustrating resist-
ance and biochemical disease 
progression on DA therapy with 
complete biochemical remission 
following surgery
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time of life or in an atypical cell, tissue or organ leading to a 
paraneopastic syndrome. However, even though cells acquire 
this ability under gene manipulation, they cannot alter their 
secretory features and may not be able to store synthesised 
peptides leading to negative staining [7].
Patients with UTROSCT typically present with metror-
rhagia and/or a uterine mass [8, 36]. This category of uter-
ine neoplasms with variable biological behaviour is divided 
into two groups: uterine tumors resembling ovarian sex 
cord tumors (UTROSCT), and the related endometrial stro-
mal tumors with sex cord-like elements (ESTSCLE) [37]. 
According to World Health Organisation (WHO), UTRO-
SCT is currently defined as the “neoplasm resembling ovar-
ian sex cord tumors without a component of recognizable 
endometrial stroma” (WHO, I.A.R.C. 2014, 4th Ed) [38]. 
UTROSCTs are rare uterine neoplasms with literature citing 
less than 80 cases in total, with only one case associated with 
ectopic prolactin. However, other reported cases of ectopic 
hyperprolactinaemia with uterine tumors have common 
characteristics with this case and it is possible that these may 
have potentially belonged to the same tumor category [25].
The cardinal features of our case were: the high prol-
actin suggestive of a macroadenoma, a normal MRI scan, 
a paradoxical rise in serum prolactin despite initiation of 
dopamine agonist therapy, and resolution of hyperprolacti-
naemia after surgical excision. Although hyperprolactinae-
mia of extracranial origin is exceptionally rare, it should be 
suspected in patients found to have very high (> 10× ULN) 
serum prolactin concentrations and normal findings on cra-
nial imaging. In cases of ectopic hyperprolactinaemia in 
premenopausal female patients this would be most often 
demonstrated by imaging of the reproductive system.
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Table 2  Summary of cases reporting on hyperprolactinaemia to a uterine neoplasm
PRL prolactin, IHC immunohistochemistry, UTROSCT uterine tumours resembling ovarian stress cord tumours
Case Year Age (years) Presenting 
symptoms
PRL con-
centration 
(mcg/L)
Response to 
medical treat-
ment
Location 
of tumour
Tumour 
size 
(cm)
Surgical treat-
ment
PRL IHC— 
Histology
Coridano V. 2005 44 Amenorrhoea 
Erythrocy-
tosis
218 No response Uterus 8 Hysterectomy Not performed 
Leiomyoma
Herzog AG 2000 36 Amenorrhoea 
Galactor-
rhoea 
Migraines
100 Deterioration Uterus 5.5 Hysterectomy Not performed 
Leiomyoma
O’Meara AC 2009 35 Galactorrhoea 
Metrorrhagia
87 None received Uterus 8.6 Hysterectomy 
BSO
Negative— 
UTROSCT
Sato et al. 2017 45 Amenorrhoea 91.5 No response Uterus 9 Hysterectomy Negative—Lei-
omyoma
Sendur et al. 2019 25 Amenorrhoea 
Galactor-
rhoea Subfer-
tility
150 No response Uterus 8 Myomectomy Negative—Lei-
omyoma
Simsir IY et al. 2012 34 Amenorrhoea 
Galactor-
rhoea
152 Deterioration Uterus 15 Hysterectomy Negative 
Mesenchymal 
tumour
Our case 2020 46 Amenorrhoea 223 Deterioration Uterus 11 Hysterectomy Negative —
UTROSCT
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